# bluebird bio and apceth Biopharma sign commercial manufacturing agreement

bluebird bio and apceth Biopharma entered a strategic manufacturing agreement for European commercial production of bluebird bio's Lenti-D and LentiGlobin gene therapy products at apceth's GMP facility in Munich.

- Type: Contract
- Announced: 2016-12-15
- Where: Munich, Germany, Germany
- Status: announced
- Products: Lenti-D gene therapy, LentiGlobin gene therapy
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [bluebird bio](https://endata.com/companies/20764.md) (customer)
- [apceth Biopharma](https://endata.com/companies/20765.md) (supplier)

## Sources

- [biotechnewswire.ai](https://www.biotechnewswire.ai/201612151512/bluebird-bio-and-apceth-biopharma-establish-commercial-drug-product-manufacturing-agreement.html), 2016-12-15: "By partnering with multiple organizations, including our valued partner apceth Biopharma, we are able to develop integrated capabilities in manufacturing."
- [emjreviews.com](https://www.emjreviews.com/general-healthcare/news/bluebird-bio-and-apceth-biopharma-establish-commercial-drug-product-manufacturing-agreement/), 2016-12-19: "By partnering with multiple organizations, including our valued partner apceth Biopharma, we are able to develop integrated capabilities in manufacturing that can position us to effectively bring our future commercial products to patients in need."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.